STOCKHOLM, March 8, 2021 /PRNewswire/ -- Calliditas
Therapeutics AB (publ) ("Calliditas") today announced the
appointment of three industry veterans: Warren Brooks, PhD, as Vice President of US
Medical Affairs, Teona Johnson as
Head of US Marketing and David
Ferraro as Head of US Sales.
Calliditas Therapeutics has bolstered its US organization with
three pharmaceutical veterans as it moves towards the potential
commercialization of its lead product candidate, Nefecon.
"This is an important step on our continued path to deliver on
our promise to build a center of excellence in the US. This shows
our long term commitment to building an organization focused on the
commercialization of orphan drugs to address unmet medical needs",
said Renee Aguiar-Lucander, CEO of
Calliditas.
Warren Brooks, PhD, joins
Calliditas from Regeneron, where he served as a Senior Director,
National Lead in Immunology in Medical Affairs. Warren was one of
the first, and key, members in establishing and building the
medical affairs organization at Regeneron, working primarily within
Immunology and Allergy. Prior to Regeneron, Warren worked at
Centocor, Inc., a subsidiary of Johnson and Johnson, and at
AstraZeneca.
Teona Johnson brings over 15
years of marketing experience, including a proven track record of
successfully launching and growing brands in the biopharmaceutical
industry. She joins Calliditas after spending over 10 years in
leadership roles in marketing at Pfizer Inc. Most recently Teona
served as the Global Commercial Director, leading the marketing
strategy for Ibrance (palbociclib), a $5+ billion oncology brand.
While at Pfizer, Teona planned and executed several launches,
including in rare indications.
David Ferraro joins Calliditas
from Kyowa Kirin, Inc., a global specialty pharmaceutical company,
where he served as the National Sales Director for the Oncology /
Rare Disease business unit. David most recently led the planning
and build out of the sales organization to achieve the successful
launch of a specialty product in oncology. Prior to Kyowa
Kirin, David held sales and marketing positions of increasing
responsibility at Daiichi Sankyo, Sanofi Aventis and Merck &
Company.
"We are very excited to welcome Teona and David to our growing
US commercial organization. Both, along with Warren, will play key
roles in the further development and execution of our strategy as
we expand our US presence," said Andrew
Udell, Head of North
America, Commercial.
For further information, please contact:
Marie Galay
IR Manager
Calliditas
Tel.: +44 79 55 98 12 45
email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on March 8, 2021 at 8:30 a.m.
CET.
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of the autoimmune renal
disease IgA nephropathy, or IgAN, for which there is a high unmet
medical need and there are no approved treatments. Calliditas is
running a global Phase 3 study within IgAN and, if approved, aims
to commercialize Nefecon in the United
States. Calliditas is also planning to conduct clinical
trials with NOX inhibitors in PBC and oncology. Calliditas is
listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global
Select Market (ticker: CALT). Visit www.calliditas.com for further
information.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Calliditas' strategy, business plans and focus, such as
the potential commercialization of Nefecon and the expansion of our
US presence. The words "may," "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, any related to Calliditas' business, operations,
clinical trials, regulatory interactions, supply chain, strategy,
goals and anticipated timelines, competition from other
biopharmaceutical companies, and other risks identified in the
section entitled "Risk Factors" Calliditas' reports filed with the
Securities and Exchange Commission. Calliditas cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. Calliditas disclaims any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent Calliditas' views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-strengthens-its-us-commercial-and-medical-affairs-organization,c3301531
The following files are available for download:
https://mb.cision.com/Main/16574/3301531/1383423.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/calliditas-strengthens-its-us-commercial-and-medical-affairs-organization-301242167.html
SOURCE Cision AB